Name: Alogliptin (SYR-322)
Price: 145.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Alogliptin (also known as SYR-322), is a novel, orally-available and highly selective quinazolinone-based inhibitor of dipeptidyl peptidase-4 (DPP-4), a serine aminopeptidase catalyzing the cleavage of peptides, that potently inhibits human DPP-4 in vitro with 50% inhibition concentration IC50 value of 6.9 nM and barely exhibits any inhibition towards the closely related serine proteases, including DPP-2, DPP-8, DPP-9, fibroblast activation protein/seprase, prolyl endopeptidas and tryptase (IC50 > 100,000 nM for all). Alogliptin prevents DPP-4-catalyzed degradation of GLP-1 and GIP, which regulate concentrations of blood glucose by stimulating glucose-dependent insulin secretion, and hence is being investigated in the treatment of type 2 diabetes.
- Properties
  - Alternative Name
    
    Alogliptin,SYR322; 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile
    
    CAS Number
    
    850649-61-5
    
    Molecular Formula
    
    C18H21N5O2
    
    Molecular Weight
    
    339.39
    
    Appearance
    
    A solid
    
    Purity
    
    98.91%
    
    Solubility
    
    insoluble in H2O; ≥100 mg/mL in EtOH with ultrasonic; ≥14.75 mg/mL in DMSO
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only
- Reference
  - 1. Hee Seok Jung, Mi Seon Seo, et al. "The anti-diabetic drug alogliptin induces vasorelaxation via activation of Kv channels and SERCA pumps." Eur J Pharmacol. 2021 May 5;898:173991. PMID:33684451
    2. Tardif V, Muir R, et al. "Adenosine deaminase-1 delineates human follicular helper T cell function and is altered with HIV." Nat Commun. 2019 Feb 18;10(1):823. PMID:30778076

Alogliptin (SYR-322)

Alogliptin (SYR-322)

Background

We Also Recommend

Atazanavir sulfate (BMS-232632-05)

GM 6001

Marimastat